Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension

缬沙坦 沙库比林 医学 奥美沙坦 血压 沙库比林、缬沙坦 单纯收缩期高血压 内科学 心脏病学 血流动力学 收缩期高血压
作者
Bryan Williams,John R. Cockcroft,Kazuomi Kario,Dion Zappe,Patrick Brunel,Qian Wang,Weinong Guo
出处
期刊:Hypertension [Lippincott Williams & Wilkins]
卷期号:69 (3): 411-420 被引量:212
标识
DOI:10.1161/hypertensionaha.116.08556
摘要

Effective treatment of systolic hypertension in elderly patients remains a major therapeutic challenge. A multicenter, double-blind, randomized controlled trial with sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor neprilysin inhibitor, was conducted to determine its effects versus olmesartan (angiotensin receptor blocker) on central aortic pressures, in elderly patients (aged ≥60 years) with systolic hypertension and pulse pressure >60 mm Hg, indicative of arterial stiffness. Patients (n=454; mean age, 67.7 years; mean seated systolic blood pressure, 158.6 mm Hg; mean seated pulse pressure, 69.7 mm Hg) were randomized to receive once-daily sacubitril/valsartan 200 mg or olmesartan 20 mg, force titrated to double the initial doses after 4 weeks, before primary assessment at 12 weeks. The study extended double-blind treatment for 12 to 52 weeks, during which amlodipine (2.5–5 mg) and subsequently hydrochlorothiazide (6.25–25 mg) were added-on for patients not achieving blood pressure target (<140/90). At week 12, sacubitril/valsartan reduced central aortic systolic pressure (primary assessment) greater than olmesartan by −3.7 mm Hg ( P =0.010), further corroborated by secondary assessments at week 12 (central aortic pulse pressure, −2.4 mm Hg, P <0.012; mean 24-hour ambulatory brachial systolic blood pressure and central aortic systolic pressure, −4.1 mm Hg and −3.6 mm Hg, respectively, both P <0.001). Differences in 24-hour ambulatory pressures were pronounced during sleep. After 52 weeks, blood pressure parameters were similar between treatments ( P <0.002); however, more patients required add-on antihypertensive therapy with olmesartan (47%) versus sacubitril/valsartan (32%; P <0.002). Both treatments were equally well tolerated. The PARAMETER study (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Measuring Arterial Stiffness in the Elderly), for the first time, demonstrated superiority of sacubitril/valsartan versus olmesartan in reducing clinic and ambulatory central aortic and brachial pressures in elderly patients with systolic hypertension and stiff arteries.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
GAOYUwenzhang完成签到,获得积分10
刚刚
champ2ons完成签到,获得积分10
1秒前
SciGPT的应助被WJS采纳,获得10
1秒前
微血管发布了新的文献求助20
1秒前
wxnice发布了新的文献求助10
1秒前
阿张完成签到,获得积分10
1秒前
绵绵冰完成签到 ,获得积分10
2秒前
Awei完成签到,获得积分10
2秒前
伯赏迎松完成签到,获得积分10
2秒前
2秒前
e个汉堡包完成签到 ,获得积分10
4秒前
幼儿园老大完成签到,获得积分10
4秒前
4秒前
4秒前
hanxi完成签到,获得积分10
4秒前
xiaozhou完成签到,获得积分10
5秒前
YY完成签到,获得积分10
5秒前
5秒前
ykzhu完成签到,获得积分10
5秒前
涵青夏完成签到 ,获得积分10
5秒前
6秒前
6秒前
科研通AI6.4的应助被dabai采纳,获得10
6秒前
七七完成签到,获得积分10
6秒前
hermit的应助被lovesxj941采纳,获得110
6秒前
ZW完成签到,获得积分10
6秒前
jeong完成签到,获得积分10
6秒前
123完成签到,获得积分10
6秒前
Orange的应助被李佳会采纳,获得10
7秒前
7秒前
7秒前
7秒前
Solitary完成签到,获得积分10
7秒前
wxnice完成签到,获得积分10
8秒前
酷波er的应助被海盐奶盖采纳,获得10
9秒前
研友_VZG7GZ的应助被峥嵘采纳,获得10
9秒前
李白完成签到,获得积分10
9秒前
10秒前
huhuan完成签到,获得积分10
10秒前
qupei完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180275
求助须知:如何正确求助?哪些是违规求助? 9570366
关于积分的说明 21810725
捐赠科研通 7776380
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479042